Literature DB >> 30982564

Effects of low-dose intraoperative fentanyl on postoperative respiratory complication rate: a pre-specified, retrospective analysis.

S Friedrich1, D Raub1, B J Teja2, S E Neves2, T Thevathasan3, T T Houle3, M Eikermann4.   

Abstract

BACKGROUND: Fentanyl is one of the most frequently administered intraoperative drugs and may increase the risk of postoperative respiratory complications (PRCs).
METHODS: We performed a pre-specified analysis of 145 735 adult non-cardiac surgical cases under general anaesthesia. Using multivariable logistic regression, we evaluated the association of intraoperative fentanyl dose and PRCs within 3 days after surgery (defined as reintubation, respiratory failure, pneumonia, pulmonary oedema, or atelectasis). We examined effect modification by patient characteristics, surgical site, and anaesthetics used.
RESULTS: PRCs within 3 days after surgery occurred in 18 839 (12.9%) patients. In comparison with high intraoperative fentanyl doses [median: 3.85; inter-quartile range (IQR): 3.42-4.50 μg kg-1, quartile 4 (Q4)], low intraoperative fentanyl dose [median: 0.80, IQR: 0.00-1.14 μg kg-1, quartile 1 (Q1)] was significantly associated with lower odds of PRCs [Q1 vs Q4: 10.9% vs 16.2%; adjusted odds ratio (aOR) 0.79; 95% confidence intervals (CI) 0.75-0.84; P<0.001; adjusted absolute risk difference (aARD) -1.7%]. This effect was augmented by thoracic surgery (P for interaction <0.001; aARD -6.2%), high doses of inhalation anaesthetics (P for interaction=0.016; aARD -2.2%) and neuromuscular blocking agents (NMBAs) (P for interaction=0.001; aARD -3.4%). Exploratory analysis demonstrated that compared with no fentanyl, low-dose fentanyl was associated with lower rates of PRCs (decile 2 vs decile 1: aOR 0.82, CI 0.75-0.89, P<0.001).
CONCLUSIONS: Intraoperative low-dose fentanyl (about 60-120 μg for a 70 kg patient) was associated with lower risk of postoperative respiratory complications compared with both no fentanyl and high-dose fentanyl. Beneficial effects of low-dose fentanyl were magnified in specific patient subgroups. CLINICAL TRIAL REGISTRATION: NCT03198208.
Copyright © 2019 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  analgesics; fentanyl; opioid; pneumonia; postoperative complications; respiratory failure; respiratory tract diseases

Mesh:

Substances:

Year:  2019        PMID: 30982564     DOI: 10.1016/j.bja.2019.03.017

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Apnoea is not necessary for flexible ureteroscopy and lasertripsy of renal stones: a prospective study over 6 years.

Authors:  Hui Ching Ho; Thomas Hughes; Amelia Pietropaolo; Carolyn Way; Sarah Prattley; Lily Whitehurst; Bhaskar K Somani
Journal:  Cent European J Urol       Date:  2020-06-06

2.  Calabadion 1 selectively reverses respiratory and central nervous system effects of fentanyl in a rat model.

Authors:  Tharusan Thevathasan; Stephanie D Grabitz; Peter Santer; Paul Rostin; Oluwaseun Akeju; James D Boghosian; Monica Gill; Lyle Isaacs; Joseph F Cotten; Matthias Eikermann
Journal:  Br J Anaesth       Date:  2020-03-30       Impact factor: 9.166

3.  Supraglottic airway device versus tracheal intubation and the risk of emergent postoperative intubation after general anaesthesia in adults: a retrospective cohort study.

Authors:  Maximilian Hammer; Peter Santer; Maximilian S Schaefer; Friederike C Althoff; Karuna Wongtangman; Ulrich H Frey; Xinling Xu; Matthias Eikermann; Philipp Fassbender
Journal:  Br J Anaesth       Date:  2020-12-17       Impact factor: 9.166

4.  S-nitroso-L-cysteine stereoselectively blunts the adverse effects of morphine on breathing and arterial blood gas chemistry while promoting analgesia.

Authors:  Paulina M Getsy; Alex P Young; James N Bates; Santhosh M Baby; James M Seckler; Alan Grossfield; Yee-Hsee Hsieh; Tristan H J Lewis; Michael W Jenkins; Benjamin Gaston; Stephen J Lewis
Journal:  Biomed Pharmacother       Date:  2022-07-26       Impact factor: 7.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.